PATENT CLAIM ANALYSIS

Application Number: 16251143
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-05
Patent Classification: ["514", "001000"]

Abstract:
The invention relates to a compound of formula: which may be in base form or in the form of a hydrate or a solvate, in combination with prednisone or prednisolone, for its use as a medicament in the treatment of prostate cancer, particularly metastatic prostate cancer, especially for patients who are not catered for by a taxane-based treatment.

Claim (Index 15):
The method according to  claim 1 , wherein said compound is administered in an amount to provide an C max  of about 226 ng\u00b7h/mL (CV 107%).

Metadata:
- Claim Count in Document: 53.0
- Percentile: 99.0
- Lexical Diversity: 1.48837
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13456720', '15627962', '15551708', '13984669', '15704726']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7361067771712455
- 35 USC 102 Novelty (BERT): 0.5760119219330126
- Combined Prediction Score: 0.7200972916474223
- Mean Citation Score: 327.969902
- Max Citation Score: 447.06128
- Similarity Product: 396.49537511320113

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test